>

Galapagos Financials

<div class='circular--portrait' style='background:#FCD202;color: white;font-size:4em;padding-top: 25px;;'>GA</div>
GLPG -- USA Stock  

Earnings Report: April 24, 2020  

Understanding current and past Galapagos Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. Galapagos Earnings before Tax are expected to significantly increase based on the last few years of reporting. The last year's Earnings before Tax were at 150.06 Million. The current year Average Equity is expected to grow to about 2.2 B, whereas Market Capitalization is expected to decline to about 11 B. We strongly advise to harness Galapagos fundamental analysis to see if markets are presently mispricing the organization. Simply put, you can make use of it to find out if Galapagos NV is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. We found thirty-three available reported financial drivers for Galapagos NV, which can be compared to its competitors. To make sure the equity is not overpriced, please check out all Galapagos financials, including its Total Debt, Number of Employees and the relationship between EBITDA and Cash Flow from Operations . Given that Galapagos NV has Price to Book of 7.17 , we strongly advise you confirm Galapagos NV regular market performance to make sure the company can sustain itself down the road. Use Galapagos to protect your portfolios against small markets fluctuations. The stock experiences very speculative upward sentiment. Check odds of Galapagos to be traded at $119.79 in 30 days.
View Fundamentals For
Refresh
With this module, you can determine Galapagos financials for your investing period. You should be able to track the changes in Galapagos individual fundamental values over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
52%52%

Chance of Financial Distress

Galapagos NV has more than 52 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info

Galapagos Company Summary

Galapagos competes with DYADIC INTERNATIONAL, DiaMedica Therapeutics, Editas Medicine, Auris Medical, and NantKwest. Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. The company was founded in 1999 and is headquartered in Mechelen, Belgium. Galapagos operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 779 people.
Foreign Associate  Austria
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
ExchangeBATS Exchange
CUSIP36315X101
LocationBelgium
Business AddressGeneraal De Wittelaan L11 A3
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.glpg.com
Phone32 1 534 29 00
CurrencyUSD - US Dollar

Galapagos Key Financial Ratios

Galapagos Financial Ratios Relationships

Galapagos NV is rated as one of the top companies in revenue category among related companies. It is rated below average in price to earnings to growth category among related companies .

Galapagos NV Systematic Risk

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Galapagos NV correlated with the market. If Beta is less than 0 Galapagos generally moves in the opposite direction as compared to the market. If Galapagos Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Galapagos NV is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Galapagos is generally in the same direction as the market. If Beta > 1 Galapagos moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

Galapagos Thematic Clasifications

Biotech Idea
BiotechView

Galapagos April 1, 2020 Opportunity Range

Please check Risk vs Return Analysis. Please also try Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page